The company maintains a strong financial position with liquid assets exceeding short-term obligations and a healthy current ratio of 3.13. InvestingPro subscribers can access detailed financial analysis and 10 additional ProTips about NBIX's market position and growth potential. This announcement is based on a press release statement issued by Neurocrine Biosciences. In other recent news, Neurocrine Biosciences has reported promising results from a Phase 2 clinical trial for its investigational drug, NBI-1117568, aimed at treating schizophrenia. The trial showed significant improvements in symptoms as early as Week 3, with the drug being well tolerated by patients. Neurocrine has already initiated a Phase 3 registrational program to further evaluate the drug's efficacy and safety.